
Citi expects 17% upside in Cipla shares but warns on delay in Abraxane launch
Citi’s commentary comes as China-based pharma company Jiangsu Hengrui has received approval for Paclitaxel, the generic version of BMS’ Abraxane.
Citi’s commentary comes as China-based pharma company Jiangsu Hengrui has received approval for Paclitaxel, the generic version of BMS’ Abraxane.
The Indian unit of South Korean carmaker Hyundai Motor will be selling its shares in the range of ₹1,865-1,960 crore to raise a total of…
The market has reacted positively to Partha Pratim Sengupta’s appointment. However, brokerages differ on the bank’s long-term outlook.
In a note dated July 31, IIFL Securities had highlighted that the Nifty Bank contributes to 50% of NSE option premium volumes and is NSE’s…
On Friday, market tech analysts Mitessh Thakkar and F&O analyst Sneha Seth recommended these stocks for the short term.
According to brokerage estimates, refining throughput at 17 mmtpa and petchem performance are expected to remain muted. Refining margins are also expected to remain subdued…
The CSI 300 Index dropped as much as 1.6% after advancing on Thursday. The gauge has now declined about 2% this week. Hong Kong’s equity…
As per the September quarter shareholding pattern disclosed to the exchanges, promoters of Adani Enterprises had a 74.89% stake in the company.
With state elections approaching in Maharashtra, Bihar, and Jharkhand—which account for 28% of the company’s total assets under management (AUM)—disruptions are anticipated, according to Nomura.
Marketbuzz Podcast: GIFT Nifty was lower this morning indicating a start in the red for the Indian market with stocks like TCS, Tata Elxsi, Anand…